Pd-Catalyzed Cyanation of a Bromoaryl Carboxylate En Route to Etrumadenant: Robust Process with Low Catalyst Loading Enabled by Preactivation-Reference-Cited by-同舟云学术

Pd-Catalyzed Cyanation of a Bromoaryl Carboxylate En Route to Etrumadenant: Robust Process with Low Catalyst Loading Enabled by Preactivation

Published:2022-11-07 Issue:11 Volume:26 Page:3161-3165
ISSN:1083-6160
Container-title:Organic Process Research & Development
language:en
Short-container-title:Org. Process Res. Dev.

Author:

Hartung John¹^ORCID,Wang Xiang¹,Song Zhiguo Jake¹,Chen You²,Guo Feng²,Li Zhifeng²

Affiliation:

1. Small Molecule Pharmaceutical Development and Manufacturing, Arcus Biosciences, 3928 Point Eden Way, Hayward, California 94545, United States

2. Shanghai SynTheAll Pharmaceutical, Co. Ltd., 90 Delin Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Physical and Theoretical Chemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.oprd.2c00272

Reference29 articles.

1. aBeatty, J.; Debien, L. P.; Jeffrey, J. L.; Leleti, M. R.; Mandal, D.; Miles, D. H.; Powers, J. P.; Rosen, B. R.; Sharif, E. U.; Thomas-Tran, R. Azolopyrimidine for the Treatment of Cancer-Related Disorders. U.S. Patent 10,399,962 B2, 2019.

2. bLeleti, M. R.; Mandal, D.; Miles, D. H.; Powers, J. P.; Rosen, B. R.; Sharif, E. U. Preparation of pyridone A2R antagonists. WO2020023846A1, 2020.

3. Abstract 4572: Characterization of the potent and selective A2aR antagonist AB928 for the treatment of cancer

4. Abstract 5556: Combining adenosine receptor inhibition with AB928 and chemotherapy results in greater immune activation and tumor control

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Palladium-Catalyzed Cyanations of Aryl Imidazolylsulfonates with K4[Fe(CN)6]: A Pragmatic Approach to Benzonitriles from Phenols;Synthesis;2024-05-22

2. A Novel and Practical Synthesis of 5-Fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carbonitrile, a Key Intermediate of Vericiguat;Organic Process Research & Development;2023-03-30